Kornimate/medical-research-clean huggingface dataset:
muscle energy technique and static stretching on pain intensity and functional disability in patients with mechanical neck pain

Conditions: Neck Pain

Summary: neck pain is becoming increasingly common throughout the world with a considerable impact on individuals, communities, health-care systems and businesses (hoy et al, 2011).neck pain is a common problem within our society affecting individual's physical and social functioning considerably and interfering with the patient's daily activities. there is lack of evidence to allow conclusions to be drawn about the effectiveness of met when compared with stretching exercises for relieving mechanical neck pain. therefore, this study is designed to examine the effect of met, static stretching and to compare their effects on pain intensity and functional disability in patient with mechanical neck pain.

this experimental study purposively recruited 24 subjects (male: n=10, female: n = 14) with mechanical neck pain from the outpatient physiotherapy department of the obafemi awolowo university teaching hospitals complex, ile-ife. subjects were randomly allocated into the met and ss groups. subjects in met group received 6 treatment sessions of muscle energy technique in addition to conventional physiotherapy treatments. patients in ss group received 6 treatment sessions of static stretching in addition to conventional physiotherapy treatments. all subjects were treated twice a week for six weeks. visual analogue scale (vas) and neck disability index (ndi) were used to assess the pain intensity and functional disability at baseline, 3rd week and 6th week of treatment sessions respectively. descriptive and inferential statistics were used to analyse the data. alpha level was set at \< 0.05.

Eligibility criteria:
inclusion criteria:i. male and female patients with history of mechanical neck pain of more than 3 months exclusion criteria: * patients with acute neck pain * subjects were excluded if they have neck pain associated with an underlying pathology such as fracture of the cervical spine, neck pain radiating into the arms or upper extremity or associated with headaches or facial pain, malignancy, infections, inflammatory disorders, osteoporosis or cases of disc prolapse. * patients with history of surgery of the cervical spine during the previous 12months

Keywords: static stretching, , neck pain, muscle energy techniques visual analogue scale, neck disability index
paclitaxel/ifosfamide/cisplatin chemotherapy for high risk pediatric germ cell tumor

Conditions: Pediatric Germ Cell Tumor

Summary: germ cell tumor has generally good prognosis, but high risk germ cell tumor has still very poor prognosis. there remains the need of further improvement with other chemotherapy strategy. especially more than 11 years old, mediastinal germ cell tumor, stage 3 or 4 extragonodal germ cell tumor or the remained tumor after the primary treatment are the group with the poorest prognosis. paclitaxel is widely used chemotherapeutic agent in adults and the experience of the agent has also been accumulated in children. the paclitaxel, ifosfamide, cisplatin (tip) regimen has been used 2nd-line treatment for germ cell tumor and there is some promising result of the role of tip in first line germ cell tumor treatment. in high risk pediatric germ cell tumor patients, tip regimen will be able to reduce lung toxicity from the bleomycin as the standard regimen and to improve the survival. in this trial, the efficacy and safety of tip as the first line treatment for germ cell tumor will be elucidated.


Eligibility criteria:
inclusion criteria: * over 1 year old and less than 20 years old * pathologically or cytologically diagnosed germ cell tumor * germ cell tumor which has not been treated previously * higher than stage ii (stage i should be excluded) * pathologic type 1. embryonal carcinoma 2. choriocarcinoma 3. yolk sac tumor 4. teratoma with malignant germ cell tumor elements * high risk definition 1. more than 11 years old, male or female 2. less than 11 years old, male or female 1. extragonodal germ cell tumor, stage iii 2. extragonodal germ cell tumor, stage iv 3. ovarian germ cell tumor, stage iv * more than 8 weeks of life expectancy * performance level : ecog performance score 0, 1, or 2 * informed consent should be obtained exclusion criteria: * pregnancy or lactating patients (fertile men or women should agree to avoid pregnancy during the trial period) * previously reported allergy or hypersensitivity to trial chemotherapeutic agent * severe hypersensitivity to the agent containing cremophor r el (polyoxyethylated castor oil) * acceptable organ functions 1. bone marrow : absolute neutrophil count \>=1000/µl , platelet \>= 100000/µl 2. renal function : serum creatinine ≤ 1.5 x upper limit of normal (uln) 3. hepatic function : total bilirubin ≤ 1.5 x uln, alt ≤ 3.0 x unl 4. cardiac function : ejection fraction ≥ 50% 5. uncontrolled infection 6. uncontrolled urinary obstruction 7. uncontrolled cystitis * followings will be excluded 1. mature teratoma 2. gliomatosis peritonei 3. low risk germ cell tumor 4. testicular stage i 5. ovarian stage i 6. recurrent, refractory tumor * concomitant other trial agent beside the agents in this trial * concomitant chemotherapeutic agents besides the agents in this trial 1. concomitant tumor other than germ cell tumor 2. other trial agents 3. other chemotherapeutic agents
cultivation of hyalocytes from ilm and erm samples: a pilot study

Conditions: Epiretinal Membrane

Summary: ilm and erm are routinely excised during surgery, as part of the surgical technique, and cultivation of hyalocytes will be performed ex vivo after surgery.

hyalocytes, typically located 20 to 50μm anterior the internal limiting membrane (ilm), have the potential to contribute to development of epiretinal membranes (erm) in presence of vitreoschisis. for macular holes, hyalocytes located on the ilm are hypothesized to contribute to the closure of the macular hole after application of the inverted ilm flap technique. ilm is routinely excised during surgical repair of macular holes. during peeling of erm it is excised in case of persisting wrinkling of the retinal surface or partial en bloc excision with the erm. furthermore, excision of ilm during erm peeling is associated with significantly lower recurrence rates of erm and better long term visual acuity, according to the results reported by chang et al. removal of erm and ilm is part of the surgical routine during surgical repair of macular holes and peeling of epiretinal membranes. therefore, cultivation of excised erm and ilm samples does not increase risks for patients in any way. during study it is planned to cultivate hyalocytes for investigation of their role in macular hole closure.

Eligibility criteria:
inclusion criteria: * macular hole or epiretinal membrane exclusion criteria: * pregnancy (pregnancy test will be taken preoperatively in women of reproductive age)
a study of nivolumab or placebo in combination with docetaxel in men with advanced castration-resistant prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.


Eligibility criteria:
inclusion criteria: * histologic confirmation of adenocarcinoma of the prostate without small cell features * current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computerized tomography/magnetic resonance imaging (ct/mri) * eastern cooperative oncology group (ecog) performance status 0-1 * ongoing androgen deprivation therapy (adt) with a gonadotropin-releasing hormone (gnrh) analogue or bilateral orchiectomy * documented prostate cancer progression per prostate cancer working group (pcwg3) criteria within 6 months prior to screening * chemotherapy-naïve for metastatic castration-resistant prostate cancer (mcrpc), with 1 to 2 prior second generation hormonal therapies in the recurrent non-metastatic setting and/or metastatic setting, and no more than 1 second generation hormonal therapy in the mcrpc setting. must have progressed during or after second generation hormonal therapy or have documented intolerance to second generation hormonal therapy * participants must meet one of the following criteria regarding tissue submission: sufficient tumor samples from a newly obtained ("fresh") biopsy (obtained during screening); or archival tumor tissue in the form of formalin-fixed paraffin-embedded (ffpe) block or unstained tumor tissue slides. for participants with bone-only disease or inaccessible soft tissue lesions or if the biopsy procedure would pose an unacceptable clinical risk for the participant, submission of tumor tissue obtained from a fresh biopsy is not required. * men must agree to follow specific methods of contraception, if applicable exclusion criteria: * active brain metastases * active, known, or suspected autoimmune disease * condition requiring systemic treatment with corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. inhaled or topical steroids or adrenal replacement steroid doses are permitted in the absence of active autoimmune disease * prior treatment with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-ctla-4 antibody, or any other antibody or drug specifically targeting t-cell co-stimulation or checkpoint pathways * prior treatment with docetaxel or other chemotherapy for mcrpc. prior docetaxel for metastatic castration-sensitive prostate cancer is permitted if at least 12 months have elapsed from last dose of docetaxel other protocol-defined inclusion/exclusion criteria apply
improving health status in covid-19 long-hauler

Conditions: Post COVID-19 Condition

Summary: this randomized clinical trial investigates the effects of a distance physical activity coaching program on the health of covid-19 long-hauler. the study evaluates the impact of individualized coaching interventions to improve participants' physical activity and quality of life.


Eligibility criteria:
inclusion criteria: * patients of both sexes. * agreed to participate. * post covid-19 condition patients meeting the who definition for this disease. * sedentary patients according to the cut-off point of the international physical activity questionnaire (ipaq). exclusion criteria: * pulmonary, cardiac, neurological, vascular, or orthopaedic pathologies that could limit the execution of the evaluation and intervention. * cognitive impairment that prevented them from understanding and answering the questionnaires. * patients suffering from a reinfection with sars-cov-2. * patients with a history of severe or critical covid-19 disease severity. * patients participating in other studies.
empagliflozin (bi 10773) dose finder study in japanese patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: this study is conducted to determine the most appropriate therapeutic doses of bi 10773 in japanese patients with t2dm at first treatment period. the second treatment period is required to obtain sufficient safety data (one-year exposure to bi 10773) in japanese patients with t2dm according to the ich e1 guideline.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus prior to informed consent * male and female patients on diet and exercise regimen who are: 1. drug-naïve, defined as no antidiabetic drugs for 10 weeks prior to informed consent. 2. pre-treated with one oral antidiabetic drug; the present antidiabetic therapy has to be unchanged for 10 weeks prior to informed consent. * hba1c at visit 1a: 1. for patients who are drug naïve: hba1c \>=7.0 to =\<10.0% 2. for patients treated with one oral antidiabetic drug: hba1c \>=6.5 to =\<9.0% * hba1c of \>=7.0% and =\<10% at visit 2 (start of run-in) exclusion criteria: * uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/l) after an overnight fast during wash-out/placebo run-in period and confirmed by a second measurement (not on the same day). * acute coronary syndromes, stroke or transient ischaemic attack within 12 weeks prior to informed consent * impaired renal function, defined as calculated egfr \<60 ml/min (mdrd formula) during screening and/or wash-out period and/or run-in phase. * bariatric surgery within the past 2 years and other gastrointestinal surgeries that induce chronic malabsorption * blood dyscrasias or any disorders causing hemolysis or unstable red blood cell (e.g. malaria, babesiosis, haemolytic anemia) * treatment with anti-obesity drugs (e.g. sibutramine, mazindol) 12 weeks prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight
nutrition360: moving to integrated and holistic disease prevention among underserved mississippians

Conditions: Cardiovascular Diseases

Summary: the objective for the study is to implement a pilot study to establish essential components to address diet quality in healthcare settings and examine what value an integrated service model delivery has for the primary prevention of cardiometabolic diseases with an initial focus on dietary behaviors. this objective will be met by 1: utilizing a multiphase optimization study design to select and optimize essential components to address diet behaviors and 2: comparing an integrated and referral-based delivery model for healthcare-based strategies that address structural and psychosocial barriers to a healthy diet for racial/ethnic minority, marginalized and disadvantaged background young to middle aged adult populations in mississippi.

the study is designed based on the multiphase optimization strategy (most), which includes three phases to prepare or screen, optimize, and evaluate multiple components of an intervention. during first optimization phase, study team will conduct essential component selection by pilot testing three common strategies used in healthcare settings to deliver structural and psychosocial interventions that address diet behaviors. the second optimization phase will include pilot testing to examine the optimization of delivery mode for the essential components identified in first phase. in each phase, participants between 25 to 50 years of age who are at risk for cvd-related premature mortality will be recruited to complete a 3-month intervention in a community based clinical setting in mississippi. the proposed project will provide foundational knowledge for components and delivery models that are the most essential and cost-effective to improve dietary behaviors among racial/ethnic minority and disadvantaged background populations in mississippi.

Eligibility criteria:
inclusion criteria: * 25 to 50 years of age * cardiovascular disease-related premature mortality risk (people living with hiv/aids or diagnosed with or familial risk for diabetes, hypertension, obesity, or metabolic syndrome) * internet access * jackson (mississippi) metropolitan statistical area residency exclusion criteria: * cancer with active treatment * chronic obstructive pulmonary disorder, emphysema, cystic fibrosis or any other major lung disease * liver or kidney dysfunction, end-stage renal disease, active hepatitis, * celiac disease, colitis, or other gastrointestinal disorders * current pregnancy or within six months postpartum at baseline * heavy drinking * unintentional weight loss of more than 5% of body weight within the past six months * recent (in the past 6 months) heart attack, stroke or other major heart surgery or event * eating disorders (anorexia or bulimia nervosa) * currently being treated for a fungus, bacteria, viral, or other infection due to weak immune system * insulin dependent diabetes
study to evaluate safety and efficacy of pf-06700841 in subjects with moderate to severe plaque psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: the purpose of this study is to determine whether pf-06700841 is safe and effective in the treatment of chronic plaque psoriasis.


Eligibility criteria:
inclusion criteria: * have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to baseline/day 1 (prior to first dose of study drug) * have a pasi score of 12 or greater and a pga score of 3 ("moderate") or 4 ("severe") at baseline/day 1 (prior to first dose of study drug) * have plaque-type psoriasis covering at least 10% of total body surface area (bsa) at baseline/day 1 (prior to first dose of study drug) * considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment) exclusion criteria: * currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed * have evidence of skin conditions (eg, eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis * cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (uvb or puva) * have previously been treated with secukinumab (cosentyx), and ixekizumab (taltz). * have taken apremilast (otezla) within 3 months of first dose of study drug. * have undergone treatment with tofacitinib within 3 months of first dose.

Keywords: plaque psoriasis
sphenopalatine block or epidural bloodpatch for post dural puncture headache: randomized controlled trial

Conditions: Post-Dural Puncture Headache

Summary: introduction: recently sphenopalatine block emerged as an alternative to epidural blood patch for post dural puncture headache but the investigators do not know if it has significant efficacy when compared to epidural blood patch. method: randomized trial where patients will randomly receive either sphenopalatine block or epidural blood patch. pain relief to no pain or low intensity pain will be the main outcome

introduction: recently sphenopalatine block emerged as an alternative to epidural blood patch for post dural puncture headache but the investigators do not know if it has significant efficacy when compared to epidural blood patch. method: randomized clinical trial where patients with moderate to severe post dural puncture pain will randomly receive either sphenopalatine block or epidural blood patch. pain relief to no pain or low intensity pain will be the main outcome. pain recurrence, survival without pain and side effects (tinitus, low back pain, new dural puncture, sore throat) will be secondary outcomes.

Eligibility criteria:
inclusion criteria: * diagnostic criteria for post dural puncture headache * moderate to severe post dural puncture headache exclusion criteria: * procedure failures: new dural puncture on epidural blood patch trial, unable to find epidural space, intolerance to insertion of nasal swabs. * follow up loss
single dose escalation study of bivatuzumab mertansine in patients with advanced squamous cell carcinoma of the head and neck

Conditions: Head and Neck Neoplasms

Summary: maximum tolerated dose (mtd), safety, pharmacokinetics, efficacy of bivatuzumab mertansine


Eligibility criteria:
inclusion criteria: 1. male and female patients aged 18 years or older 2. patients with histologically confirmed squamous cell carcinoma of the head and neck 3. patients with local and / or regional recurrent disease or distant metastases who are refractory to or not amenable to established treatments 4. measurable tumour deposits by one or more radiological techniques (mri, ct) 5. life expectancy of at least 6 months 6. eastern cooperative oncology group (ecog) performance score ≤ 2 7. patients must have given written informed consent (which must be consistent with international conference of harmonisation-good clinical practice (ich-gcp) and local legislation) exclusion criteria: 1. hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients of the trial drugs 2. known secondary malignancy requiring therapy 3. active infectious disease 4. brain metastases 5. neuropathy grade 2 or above (excluding pre-existing neuropathy of cranial nerves due to surgery, radiotherapy or tumour growth) 6. absolute neutrophil count less than 1,500/mm3 7. platelet count less than 100,000/mm3 8. bilirubin greater than 1.5 mg/dl (\> 26 μmol/l, système internationale (si) unit equivalent) 9. aspartate amino transferase (ast) and/or alanine amino transferase (alt) greater than 3 times the upper limit of normal 10. serum creatinine greater than 1.5 mg/dl (\> 132 μmol/l, si unit equivalent) 11. concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug 12. chemo- or immunotherapy within the past three weeks prior to treatment with the trial drug or during the trial 13. radiotherapy to head and neck region within the past four weeks before inclusion or during the trial 14. men and women who are sexually active and unwilling to use a medically acceptable method of contraception 15. pregnancy or lactation 16. treatment with other investigational drugs or participation in another clinical trial within the past three weeks before start of therapy or concomitantly with this trial 17. patients unable to comply with the protocol
hematological clozapine monitoring with a point-of-care device (chempaq)

Conditions: Schizophrenia

Summary: clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of patients not responding to other antipsychotics will respond to clozapine. however, the use of clozapine is restricted due to the risk of agranulocytosis and consequently the need for mandatory hematological monitoring. chempaq xbc is a point-of-care device that can be used in patients home and analyze wbc and granulocytes by a single capillary blood drop. this study aims to investigate whether this new procedure increases the acceptability of clozapine


Eligibility criteria:
inclusion criteria: * treated with clozapine * compliant with blood monitoring * willing to give informed consent exclusion criteria: * prior case of agranulocytosis

Keywords: clozapine hematological monitoring chempaq granulocytes wbc
dynamic alterations of th2/th1 with new onset of community-acquired severe sepsis patients

Conditions: Sepsis

Summary: to evaluate the dynamic alterations of th2/th1 for the prediction of clinical immunity and how it was related to 28 day-prognosis and icu-acquired infections among critically ill patients of community-acquired severe sepsis with new onset.


Eligibility criteria:
for community-acquired severe sepsis group: inclusion criteria: * at least 18 years of age and no more than 90 years of age * sepsis was defined according to consensus criteria * diagnosis of sepsis and complicatied with organ dysfunction no longer than 48 h * provided written informed consent. exclusion criteria: * diagnosis of hematological,immunological disease or cancer * treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization for non-severe sepsis icu control group: inclusion criteria: * at least 18 years of age and no more than 90 years of age * without diagnosis of sepsis and admitted to icu * provided written informed consent. exclusion criteria: * diagnosis of hematological,immunological disease or cancer * treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization for healthy control group: inclusion criteria: * at least 18 years of age and no more than 90 years of age * provided written informed consent. exclusion criteria: * diagnosis of hematological,immunological disease or cancer * treatment with chemotherapy agents or corticosteroids within 6 months prior to enrollment

Keywords: immunosuppression community-acquired sepsis mortality